Author: Tiwari, Vaibhav; Beer, Jacob C.; Sankaranarayanan, Nehru Viji; Swanson-Mungerson, Michelle; Desai, Umesh R.
Title: Discovering small-molecule therapeutics against SARS-CoV-2 Cord-id: 043w3zgy Document date: 2020_6_20
ID: 043w3zgy
Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global health pandemic. The lack of effective treatments, coupled with its etiology, has resulted in more than 400,000 deaths at the time of writing. The SARS-CoV-2 genome is highly homologous to that of SARS-CoV, the causative agent behind the 2003 SARS outbreak. Based on prior reports, clinicians have pursued the off-label use of several antiviral drugs, while the scientific community has responded by seeking age
Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global health pandemic. The lack of effective treatments, coupled with its etiology, has resulted in more than 400,000 deaths at the time of writing. The SARS-CoV-2 genome is highly homologous to that of SARS-CoV, the causative agent behind the 2003 SARS outbreak. Based on prior reports, clinicians have pursued the off-label use of several antiviral drugs, while the scientific community has responded by seeking agents against traditional targets, especially viral proteases. However, several avenues remain unexplored, including disrupting E and M protein oligomerization, outcompeting host glycan–virus interactions, interfering with the heparan sulfate proteoglycans–virus interaction, and others. In this review, we highlight some of these opportunities while summarizing the drugs current in use against coronavirus 2019 (COVID-19).
Search related documents:
Co phrase search for related documents- abelson inhibitor and abl abelson: 1
- abelson inhibitor kinase and abl abelson: 1
- abundant protein and acid residue: 1
- acid residue and action mechanism: 1, 2, 3
- acid residue and additional target: 1
Co phrase search for related documents, hyperlinks ordered by date